US Patent No: 8,329,900

Number of patents in Portfolio can not be more than 2000

Dipeptidyl peptidase inhibitors

ALSO PUBLISHED AS: 20080108808

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a compound comprising:

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Related Publications

Loading Related Publications... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
TAKEDA PHARMACEUTICAL COMPANY LIMITEDOSAKA922

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Elder, Bruce J Wynantskill, NY 17 84
Feng, Jun Carlsbad, CA 104 699
Gwaltney, Stephen L - 61 300
Isbester, Paul K Castleton, NY 29 96
Palmer, Grant J Clifton Park, NY 30 96
Salsbury, Jonathon S Albany, NY 23 66
Stafford, Jeffrey A San Diego, CA 118 578
Ulysse, Luckner G Albany, NY 15 67
Zhang, Zhiyuan San Diego, CA 72 506

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PROSIDION LIMITED (16)
6,548,481 Effectors of dipeptidyl peptidase IV 84 2000
6,500,804 Method for the improvement of islet signaling in diabetes mellitus and for its prevention 47 2001
2002/0006,899 Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals 55 2001
2002/0071,838 Method for raising the blood glucose level in mammals 35 2001
2002/0110,560 Use of dipeptidyl peptidase IV effectors for normalizing the blood glucose level in mammals 36 2002
2003/0135,023 Peptide structures useful for competitive modulation of dipeptidyl peptidase IV catalysis 34 2002
2002/0198,242 Method for the improvement of islet signaling in diabetes mellitus and for its prevention 32 2002
2003/0008,905 Method for the improvement of islet signaling in diabetes mellitus and for its prevention 32 2002
2003/0176,357 Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels 40 2002
2003/0148,961 Peptidyl ketones as inhibitors of DPIV 34 2002
2004/0058,876 Secondary binding site of dipeptidyl peptidase IV (DP IV) 30 2002
2003/0125,304 Substituted amino ketone compounds 47 2002
2003/0134,802 Novel effectors of dipepetidyl peptidase IV 47 2003
2003/0232,761 Novel analogues of glucose-dependent insulinotropic polypeptide 32 2003
2004/0229,848 Glutaminyl based DP IV-inhibitors 43 2004
2005/0014,946 Substituted amino ketone compounds 27 2004
 
TAKEDA PHARMACEUTICAL COMPANY LIMITED (16)
2004/0242,568 Dipeptidyl peptidase inhibitors 28 2004
2004/0259,870 Dipeptidyl peptidase inhibitors 28 2004
2005/0065,148 Dipeptidyl peptidase inhibitors 18 2004
2005/0070,531 Dipeptidyl peptidase inhibitors 18 2004
2005/0070,535 Dipeptidyl peptidase inhibitors 19 2004
2005/0070,706 Dipeptidyl peptidase inhibitors 17 2004
2005/0075,330 Dipeptidyl peptidase inhibitors 17 2004
2005/0065,144 Dipeptidyl peptidase inhibitors 30 2004
2005/0065,145 Dipeptidyl peptidase inhibitors 25 2004
7,807,689 Dipeptidyl peptidase inhibitors 3 2005
2006/0135,767 Dipeptidyl peptidase inhibitors 33 2005
2007/0060,528 ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS 19 2006
2007/0060,530 ADMINISTRATION OF DIPEPTIDYL PEPTIDASE INHIBITORS 29 2006
2007/0066,635 POLYMORPHS OF BENZOATE SALT OF 2-[[6-[(3R)-3-AMINO-1-PIPERIDINYL]-3,4-DIHYDRO-3-METHYL-2,4-DIOXO-1(2H)-P-YRIMIDINYL]METHYL]-BENZONITRILE AND METHODS OF USE THEREFOR 16 2006
7,795,428 Dipeptidyl peptidase inhibitors 4 2007
7,781,584 Dipeptidyl peptidase inhibitors 4 2007
 
NOVARTIS AG (10)
6,011,155 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 123 1997
6,107,317 N-(substituted glycyl)-thiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 55 1999
6,110,949 N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 82 1999
6,172,081 Tetrahydroisoquinoline 3-carboxamide derivatives 61 1999
6,124,305 Use of N-(substituted glycyl)-2-cyanopyrrolidines in inhibiting dipeptidyl peptidase-IV 68 1999
6,166,063 N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 105 1999
6,617,340 N-(substituted glycyl)-pyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 53 2000
6,559,188 Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes 36 2000
6,608,038 Methods and compositions for treatment of diabetes and related conditions via gene therapy 31 2001
6,432,969 N-(substituted glycyl)-2 cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV 83 2001
 
NOVO NORDISK A/S (10)
6,458,924 Derivatives of GLP-1 analogs 77 1999
6,380,398 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV 54 2001
6,645,995 Therapeutically active and selective heterocyclic compounds that are inhibitors of the enzyme DPP-IV 45 2002
2003/0203,946 Glucagon antagonists/inverse agonists 29 2002
2003/0186,963 Substituted piperidines 27 2002
2003/0171,411 Amide derivatives as therapeutic agents 52 2002
2003/0144,206 Combined use of a GLP-1 compound and modulator of diabetic late complications 33 2002
2003/0199,528 Hetrocyclic compounds that are inhibitors of the enzyme DPP-IV 80 2003
2003/0236,272 Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states 61 2003
2004/0054,171 Polymorphic forms of a 4H-thieno[3,2-E]-1,2,4-thiadiazine 1,1-dioxide derivative 27 2003
 
BRISTOL-MYERS SQUIBB COMPANY (9)
6,548,529 Heterocyclic containing biphenyl aP2 inhibitors and method 79 2000
6,555,519 O-glucosylated benzamide SGLT2 inhibitors and method 48 2001
6,620,821 HMG-CoA reductase inhibitors and method 41 2001
6,627,636 HMG-CoA reductase inhibitors and method 33 2001
6,727,271 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method 35 2002
6,573,287 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method 49 2002
6,673,815 Substituted acid derivatives useful as antidiabetic and antiobesity agents and method 37 2002
2004/0009,972 Benzodiazepine inhibitors of mitochondial F1F0 ATP hydrolase and methods of inhibiting F1F0 ATP hydrolase 52 2003
2004/0132,732 Quinazolinones and derivatives thereof as factor Xa inhibitors 29 2003
 
BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (8)
2002/0155,565 FAP-activated anti-tumor compounds 27 2001
2003/0055,052 FAP-activated anti-tumor compounds 27 2001
2002/0198,205 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 89 2002
2004/0166,125 Xanthine derivatives, their preparation and their use in pharmaceutical compositions 57 2003
2004/0087,587 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 82 2003
2004/0138,214 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 76 2003
2004/0138,215 Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions 60 2003
2004/0077,645 Xanthine derivatives,production and use thereof as medicament 86 2003
 
PFIZER INC. (6)
2003/0166,662 Treatment of the insulin resistance syndrome 26 2003
6,710,040 Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors 47 2003
2004/0110,817 Dipeptidyl peptidase IV inhibiting fluorinated cyclic amides 51 2003
2004/0132,713 Fluorinated cyclic amides as dipeptidyl peptidase IV inhibitors 27 2003
2004/0242,898 Synthesis of 3,3,4,4-tetrafluoropyrrolidine and novel dipeptidyl peptidase-IV inhibitor compounds 41 2004
2005/0043,292 Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors 46 2004
 
Eli Lilly and Company (5)
5,512,549 Glucagon-like insulinotropic peptide analogs, compositions, and methods of use 148 1994
5,614,379 Process for preparing anti-obesity protein 69 1995
6,006,753 Use of GLP-1 or analogs to abolish catabolic changes after surgery 94 1997
6,555,521 Glucagon-like peptide-1 crystals 35 2001
2003/0060,412 Process for solubilizing glucagon-like peptide 1compounds 28 2002
 
HOFFMANN-LA ROCHE INC. (5)
6,861,440 DPP IV inhibitors 47 2002
6,727,261 Pyrido[2,1-A]Isoquinoline derivatives 54 2002
6,867,205 Pyridine and pyrimidine derivatives 42 2003
6,800,650 Pyridine and quinoline derivatives 44 2003
2004/0259,902 Pyrido [2,1-a] isoquinoline derivatives 42 2004
 
FERRING B.V. (4)
5,939,560 Inhibitors of DP-mediated processes, compositions and therapeutic methods thereof 104 1996
6,201,132 Inhibitors of DP-mediated processes, compositions, and therapeutic methods thereof 58 1999
6,521,644 Compositions for promoting growth 28 2002
2004/0209,891 Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV 29 2004
 
TUFTS UNIVERSITY (4)
4,935,493 Protease inhibitors 98 1987
5,462,928 Inhibitors of dipeptidyl-aminopeptidase type IV 88 1993
5,580,979 Phosphotyrosine peptidomimetics for inhibiting SH2 domain interactions 69 1994
6,485,955 Quiescent cell dipeptidyl peptidase: a novel cytoplasmic serine protease 26 1999
 
DARA BIOSCIENCES, INC. (3)
6,258,597 Stimulation of hematopoietic cells in vitro 51 1998
6,355,614 Cyclic boroproline compounds 46 1999
6,703,238 Methods for expanding antigen-specific T cells 35 2001
 
DR. REDDY'S LABORATORIES LIMITED (3)
5,885,997 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases 49 1996
5,985,884 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases 48 1997
6,310,069 Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases 27 2000
 
LES LABORATOIRES SERVIER (3)
6,620,910 Peptide compounds analogues of the glucagon-like peptide-1 (7-37) 39 1999
6,716,843 Alpha-amino acid sulphonyl compounds 46 2002
6,706,742 Alpha-amino-acid compounds 49 2002
 
PHARMACIA CORPORATION (3)
6,545,170 2-amino-5, 6 heptenoic acid derivatives useful as nitric oxide synthase inhibitors 34 2001
6,495,544 Homoiminopiperidinyl hexanoic acid inhibitors of inducible nitric oxide synthase 34 2001
2005/0014,732 Combination of an aldosterone receptor antagonist and an anti-diabetic agent 27 2004
 
Cytovia, Inc. (2)
6,342,611 Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for capsases and other enzymes and the use thereof 37 1998
6,335,429 Fluorogenic or fluorescent reporter molecules and their applications for whole-cell fluorescence screening assays for caspases and other enzymes and the use thereof 49 2000
 
DANA-FARBER CANCER INSTITUTE, INC. (2)
6,325,989 Form of dipeptidylpeptidase IV (CD26) found in human serum 33 1995
6,265,551 Form of dipeptidylpeptidase IV (CD26) found in human serum, antibodies thereto, and uses thereof 35 1996
 
DIATIDE, INC. (2)
5,366,862 Method for generating and screening useful peptides 46 1992
5,814,460 Method for generating and screening useful peptides 28 1995
 
DRUCKER, DANIEL (2)
6,803,357 Method of regulating glucose metabolism, and reagents related thereto 61 2001
2003/0153,509 Method of regulating glucose metabolism, and reagents related thereto 50 2002
 
PROTHERA, INC. (2)
6,251,391 Compositions containing dipepitidyl peptidase IV and tyrosinase or phenylalaninase for reducing opioid-related symptons 32 1999
6,447,772 Compositions and methods relating to reduction of symptoms of autism 29 1999
 
ROYALTY PHARMA COLLECTION TRUST (2)
6,303,661 Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals 151 1998
6,319,893 Raising blood sugar level in hypoglycemic mammals by administering inhibitors of dipeptidyl peptidase IV 56 1999
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (2)
6,235,493 Amino acid substituted-cresyl violet, synthetic fluorogenic substrates for the analysis of agents in individual in vivo cells or tissue 38 1998
6,448,045 Inducing insulin gene expression in pancreas cells expressing recombinant PDX-1 23 2000
 
The Research Foundation of State University of New York (2)
6,573,096 Compositions and methods for inhibition of cancer invasion and angiogenesis 31 2000
2002/0132,979 Compositions and methods for inhibition of cancer invasion and angiogenesis 29 2001
 
TRUSTEES OF TUFTS COLLEGE (2)
5,965,532 Multivalent compounds for crosslinking receptors and uses thereof 66 1997
6,825,169 Inhibitors of dipeptidyl-aminopeptidase type IV 37 1997
 
114936 ONTARIO INC. (1)
2003/0040,478 Chemotherapy treatment 25 2002
 
ABBVIE INC. (1)
2004/0259,843 Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV) 32 2004
 
AJINOMOTO CO., INC. (1)
5,811,278 Dipeptidyl peptidase IV from Xanthomonas maltophilia and process for producing the same 25 1996
 
AMGEN INC. (1)
5,601,986 Assays and devices for the detection of extrahepatic biliary atresia 31 1994
 
ASTRAZENECA AB (1)
6,395,767 Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method 101 2001
 
B.M.R.A. Corporation B.V. (1)
6,337,069 Method of treating rhinitis or sinusitis by intranasally administering a peptidase 26 2001
 
BOEHRINGER INGELHEIM INTERNATIONAL GMBH (1)
2005/0026,921 New imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions 69 2004
 
Boehringer Ingelheim Pharmaceuticals, Inc. (1)
2003/0103,968 Use of alpha specific antibody BIBH1 in the treatment of cancer 28 2002
 
Chevron Research Company (1)
4,494,978 Herbicidal N-(N'-hydrocarbyloxycarbamylalkyl)-2,6-dialkyl-alpha-haloacetanilides 26 1976
 
CORNELL UNIVERSITY (1)
5,811,281 Immortalized intestinal epithelial cell lines 27 1994
 
Cytokinetics, Inc. (1)
7,230,000 Methods and compositions utilizing quinazolinones 30 2000
 
EISAI CO., LTD. (1)
2004/0116,328 Condensed imidazole derivatives 82 2003
 
FondaTech Benelux N.V. (1)
6,090,786 Serine proteases, their activity and their synthetic inhibitors 48 1997
 
GEORGIA TECH RESEARCH CORPORATION (1)
5,543,396 Proline phosphonate derivatives 76 1994
 
GUILFORD PHARMACEUTICALS INC. (1)
2004/0152,745 Dipeptidyl peptidase IV inhibitors and methods of making and using dipeptidyl peptidase IV inhibitors 38 2003
 
HIGH POINT PHARMACEUTICALS, LLC (1)
6,673,829 Aminoazetidine,-pyrrolidine and -piperidine derivatives 32 2002
 
ICOS CORPORATION (1)
6,518,277 Inhibitors of human phosphatidylinositol 3-kinase delta 71 2001
 
KEYNEUROTEK PHARMACEUTICALS AG (1)
2004/0147,434 Use of enzyme inhibitors of the dipeptidypeptidase iv (ec3.3.14.5) in addition to the aminopeptidase n (ec 3.4.11.2), individually or in a combination thereof, and pharmaceutical preparations thereof for the prevention and/or therapy of ischaemia-caused acute and chronic neurodegenerative process and illnesses, for example 31 2004
 
KISSEI PHARMACEUTICAL CO., LTD. (1)
2004/0138,148 Glucopyranosyloxybenzylbenzene derivatives and medicinal use thereof 49 2004
 
KYOWA HAKKO KOGYO CO., LTD. (1)
2004/0180,925 Dipeptidylpeptidase-IV inhibitor 68 2003
 
MACRONIX INTERNATIONAL CO., LTD. (1)
2003/0089,935 Non-volatile semiconductor memory device with multi-layer gate insulating structure 28 2001
 
MERCK & CO., INC. (1)
5,387,512 Preparation of 3-[z-benzoxazol-2-yl)ethyl]-5-(1-hydroxyethyl)-6-methyl-2-(1H)-pyridinone by biotransformation 28 1992
 
MERCK SHARP & DOHME CORP. (1)
6,699,871 Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes 90 2002
 
MITSUBISHI PHARMA CORPORATION (1)
2004/0259,883 Thiazolidine derivative and medicinal use thereof 49 2004
 
NESTEC S.A. (1)
6,309,868 Cloning of the prolyl-dipeptidyl-peptidase from Aspergillus oryzae 27 2000
 
NEWCASTLE UNIVERSITY VENTURES LIMITED (1)
6,156,739 Quinazolinone compounds 33 1999
 
NOVOZYMES, INC. (1)
6,184,020 Polypeptides having aminopeptidase activity and nucleic acids encoding same 28 1998
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
6,686,337 Combination therapy comprising anti-diabetic and anticonvulsant agents 43 2001
 
OTSUKA PHARMACEUTICAL FACTORY, INC. (1)
5,798,344 Phosphonic ester derivatives of quinazolinones 32 1996
 
PROBIODRUG AG (1)
2003/0130,199 Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents 51 2002
 
RHODE ISLAND HOSPITAL (1)
6,129,911 Liver stem cell 38 1998
 
RODOB DRUG RESEARCH INC. (1)
5,624,894 Brain-enhanced delivery of neuroactive peptides by sequential metabolism 68 1995
 
SAINT LOUIS UNIVERSITY (1)
6,261,794 Methods for identifying inhibitors of methionine aminopeptidases 28 1999
 
SCHERING CORPORATION (1)
6,664,273 Piperidine based MCH antagonists for treatment of obesity and CNS disorders 24 2002
 
SYITX, INC. (1)
2004/0254,226 Dipeptidyl peptidase inhibitors 43 2004
 
SYNX, INC. (1)
2004/0242,566 Dipeptidyl peptidase inhibitors 28 2004
 
TAISHO PHARMACEUTICAL CO., LTD. (1)
2004/0072,892 Cyanopyrrolidine derivatives 59 2003
 
TAKEDA CHEMICAL INDUSTRIES, LTD. (1)
4,824,848 Pyrazolo[3,4-d]pyrimidine derivatives, their production and use 8 1987
 
TAKEDA PHARMACEUTICAL COMPANY, INC. (1)
2008/0003,283 DIPEPTIDYL PEPTIDASE INHIBITORS 17 2007
 
THE GENERAL HOSPITAL CORPORATION (1)
5,614,492 Insulinotropic hormone GLP-1 (7-36) and uses thereof 116 1993
 
TORRENT PHARMACEUTICALS LTD. (1)
2004/0106,802 Novel compounds and therapeutic uses thereof 35 2003
 
VACCINOGEN INC. (1)
5,433,955 Site specific in vivo activation of therapeutic drugs 68 1993
 
VANDERBILT UNIVERSITY (1)
6,586,198 Method of identifying susceptibility to angiotensin converting enzyme inhibto- and vasopeptidase-inhibitor-associated angioedema 27 2001
 
Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai (1)
6,214,340 Physiologically active substance sulphostin, process for producing the same, and use thereof 24 2000
 
ZEALAND PHARMA A/S (1)
6,528,486 Peptide agonists of GLP-1 activity 65 2000
 
Other [Check patent profile for assignment information] (9)
2003/0060,434 COMBINED TUMOR SUPPRESSOR GENE THERAPY AND CHEMOTHERAPY IN THE TREATMENT OF NEOPLASMS 19 1999
2002/0061,839 Serine peptidase modulators 27 2001
2002/0037,829 Use of DPPIV inhibitors as diuretic and anti-hypertensive agents 33 2001
2002/0165,164 New effectors of dipeptidyl peptidase IV for topical use 28 2002
2002/0193,390 Pharmaceutical compositions containing an N-(substituted glycyl)-2-cyanopyrrolidine and at least one other antidiabetic agent and their use in inhibiting dipeptidyl peptidase-IV 34 2002
2003/0139,434 Combinations comprising dipeptidylpeptidase-iv inhibitor 39 2002
2003/0171,358 New compounds, their preparation and use 26 2003
2008/0108,807 DIPEPTIDYL PEPTIDASE INHIBITORS 16 2007
2008/0108,808 DIPEPTIDYL PEPTIDASE INHIBITORS 16 2007

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Jun 11, 2016
7.5 Year Payment $3600.00 $1800.00 $900.00 Jun 11, 2020
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jun 11, 2024
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00